Froeschl, Michael

Froeschl, Michael
Froeschl, Michael
MDCM, MSc, FRCPC, FACC
Phone
613-696-7318
Fax
613-696-7244

Appointments and affiliations

Interventional Cardiologist
University of Ottawa Heart Institute

Associate Professor, Department of Medicine
University of Ottawa

Dr. Michael Froeschl is an Interventional Cardiologist at the University of Ottawa Heart Institute and an Associate Professor in the Department of Medicine at the University of Ottawa.

Background

Dr. Froeschl received his bachelor’s degree from Harvard University in Cambridge, Massachusetts, and his medical degree from McGill University in Montreal. His clinical training includes three years at the University of Toronto in Internal Medicine and four years at the University of Ottawa Heart Institute - three in Adult Cardiology and a fourth in Interventional Cardiology. He was admitted as a Fellow of the Royal College of Physicians of Canada in Internal Medicine in 2003 and in cardiology in 2005. He joined the University of Ottawa Heart Institute in July 2006.

Research and clinical interests

Dr. Froeschl’s clinical interests include interventional cardiology, cardiac critical care, and general cardiology. His chief academic interest is medical education. In 2007, Dr. Froeschl won the Royal College of Physicians and Surgeons of Canada Fellowship for Studies in Medical Education.  In 2011, he completed a master’s degree in health professions education in the Faculty of Medicine at Maastricht University in the Netherlands.

Publications

LATEST PUBLICATIONS

  • Le May MR, Wells GA, Glover CA, So DY, Froeschl M , Marquis J-F, O'Brien ER, Turek M, Thomas A, Kass M, Jadhav S, Labinaz M. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of Integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Intervent 2009;2:330-338.
  • So D, Cook EF, LeMay M, Glover C, Williams W, Ha A, Davies R, Froeschl M , Marquis JF, O'Brien E, Labinaz M. Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: Observations from the Ottawa Heart Institute PCI registry. J Invasive Cardiol 2009;21(3):121-127.
  • Chong A, Labinaz M, So D, Froeschl M , Glover C, Jadhav ST, Marquis J, O’Brien ER, Wells GA, Fong M, Le May M. Outcomes of primary percutaneous coronary intervention for ST-elevation myocardial infarction during off-hours and normal working hours. 2009.
  • Le May M, Labinaz M, So D, Glover C, Froeschl M , O’Brien E, Marquis J, Fong M, Thomas A, Wells GA. Should glycoprotein IIB/IIIA receptor inhibitors be used routinely during primary PCI in patients pre-treated with high-dose clopidogrel? Can J Card 2009;25(suppl B):166B.
  • Chong A, Labinaz M, So D, Froeschl M , Glover C, Jadhav ST, Marquis J, O’Brien ER, Wells GA, Fong M, Le May M. Outcomes of primary percutaneous coronary intervention for ST-elevation myocardial infarction during off-hours and normal working hours: results from a Canadian regional STEMI program. Can J Card 2009;25(suppl B):168B.

PAPERS IN REFEREED JOURNALS

  • Le May MR, Wells GA, Glover CA, So DY, Froeschl M , Marquis J-F, O'Brien ER, Turek M, Thomas A, Kass M, Jadhav S, Labinaz M. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of Integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc Intervent 2009;2:330-338.
  • So D, Cook EF, LeMay M, Glover C, Williams W, Ha A, Davies R, Froeschl M , Marquis JF, O'Brien E, Labinaz M. Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: Observations from the Ottawa Heart Institute PCI registry. J Invasive Cardiol 2009;21(3):121-7.
  • Chong A, Labinaz M, So D, Froeschl M , Glover C, Jadhav ST, Marquis J, O’Brien ER, Wells GA, Fong M, Le May M. Outcomes of primary percutaneous coronary intervention for ST-elevation myocardial infarction during off-hours and normal working hours. 2009.
  • Le May M, Labinaz M, So D, Glover C, Froeschl M , O’Brien E, Marquis J, Fong M, Thomas A, Wells GA. Should glycoprotein IIB/IIIA receptor inhibitors be used routinely during primary PCI in patients pre-treated with high-dose clopidogrel? Can J Card 2009;25(suppl B):166B.
  • Chong A, Labinaz M, So D, Froeschl M , Glover C, Jadhav ST, Marquis J, O’Brien ER, Wells GA, Fong M, Le May M. Outcomes of primary percutaneous coronary intervention for ST-elevation myocardial infarction during off-hours and normal working hours: results from a Canadian regional STEMI program. Can J Card 2009;25(suppl B):168B.
  • LeMay MR, Do DY, Dionne R, Glover CA, Froeschl M , Wells GA, Davies RF, Sherrard HL, Maloney J, Marquis J-F, O’Brien ER, Trickett J, Poirier P, Ryan SC, Ha A, Joseph PG, Labinaz M. A city-wide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008;358:231-40.
  • Froeschl M , Wolfsohn A, Beauchesne LM. Ruptured mycotic pseudoaneurysm of the thoracic aorta. Cardiovasc Pathol 2006;15:116-8.
  • Froeschl M , Haddad H, Commons SA, Veinot JP. Thyrotoxicosis: an uncommon cause of heart failure. Cardiovasc Pathol 2005;14:24-7.
  • Froeschl M , Olsen S, Ma X, O’Brien ER. Current understanding of in-stent restenosis and the potential benefit of drug-eluting stents. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:103-17.
  • Lam C, Badiwala MV, Froeschl M . Morning report: truth serum. University of Toronto Medical Journal 2002;79:136-41.
  • Tohen M, Zarate CA, Centorrino F, Hegarty JI, Froeschl M , Zarate SB. Risperidone in the treatment of mania. Journal of Clinical Psychiatry 1996;57:249-53.

ABSTRACT

  • Jadhav ST, So D, Chong A, Fong M, Froeschl M , Marquis J, Williams W, O’Brien ER, Glover C, Wells GA, Labinaz M, Le May M. The prognostic value of mean platelet volume in patients undergoing primary PCI for ST-elevation myocardial infarction. Can J Card 2009;25(suppl B):168B.
  • Ghosh N, Fong M, So DY, Glover C, Froeschl M , Wells GA, Marquis JF, O’Brien ER, Labinaz M, Le May MR. The impact of baseline renal dysfunction on clinical outcomes after primary PCI for ST-elevation myocardial infarction in a regionalized primary PCI program. Can J Card 2009;25(suppl B):284B.
  • Le May M, Labinaz M, So D, Glover C, Froeschl M , O’Brien ER, Marquis J, Fong M, Sherrard H, Doucette P, Poirier P, Trickett J, Maloney J, Dionne R, Wells GA. Sustainability of a regional systematic program of primary percutaneous coronary intervention for ST segment elevation myocardial infarction: the Ottawa experience. Can J Card 2009;25(suppl B):297B.
  • Le May M, Labinaz M, Glover C, So D, O’Brien ER, Marquis J, Froeschl M , Fong M, Sherrard H, Wells GA, Trickett J, Dionne R, Poirier P, Maloney J. Lower hospital mortality with primary percutaneous coronary intervention when paramedics transport patients directly from the field to a cardiac center compared to when paramedics transport patients to the neatesr emergency department. Can J Card 2009;25(suppl B):297B.
  • Le May M, Wells GA, Glover C, So DY, Froeschl M , Marquis J, O’Brien ER, Turek M, Thomas A, Abarbanel T, Labinaz M. A safety and efficacy study of Integrilin plus unfractionated heparin versus unfractionated heparin alone in patients with acute ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: the ASSIST trial. Can J Card 2008;24(suppl E):348E.
  • Syed A, Fong M, Joseph P, Wells GA, Labinaz M, So D, Glover C, Marquis J, Williams W, Froeschl M , O’Brien E, Le May M. Door-to-balloon time and survival in elderly patients: time does matter. Can J Card 2008;24(suppl E):265E.
  • Syed A, Le May M, Fong M, Labinaz M, So D, Glover C, Marquis J, Williams W, Froeschl M , O’Brien E, Joseph P, Wells GA. Impact of citywide systematic primary percutaneous coronary intervention on outcomes of ST-segment elevation myocardial infarction in elderly patients. Can J Card 2008;24(suppl E):263E.
  • Fong M, Le May M, Labinaz M, So D, Glover C, Marquis J, Williams W, Froeschl M , O’Brien E, Wells GA. Critical time intervals in women versus men treated with primary angioplasty for ST-segment myocardial infarction (STEMI). Can J Card 2008;24(suppl E):234E.
  • Rahman M, Labinaz M, Allan R, Fong M, So D, Glover C, Marquis J, Williams W, Froeschl M , O’Brien E, Sookur D, Wells GA, Le May M. Safety of pre-discharge staged percutaneous coronary intervention (PCI) for patients with multivessel coronary disease undergoing emergency PCI for acute ST-elevation myocardial infarction (STEMI): observations from Ottawa Heart Institute’s (OHI) STEMI database. Can J Card 2008;24(suppl E):125E.
  • Rahman M, Labinaz M, Allan R, Fong M, So D, Glover C, Marquis J, Williams W, Froeschl M , O’Brien E, Sookur D, Wells GA, Le May M. Safety of pre-discharge staged percutaneous coronary intervention (PCI) for patients with multivessel coronary disease undergoing emergency PCI for acute ST-elevation myocardial infarction (STEMI): observations from Ottawa Heart Institute’s (OHI) STEMI database. Am J Cardiol 2008;102(8, suppl):71i.
  • Le May MR, Joseph P, So D, Glover C, Froeschl M , Marquis J, Ha A, O’Brien E, Williams WL, Labinaz M. Diabetic patients treated with primary angioplasty: results from a metropolitan area program. Can J Card 2007;23(suppl C):55C.
  • Ha A, Le May MR, Labinaz M, Dionne R, Maloney J, Glover C, So D, Marquis JF, O’Brien E, Froeschl M , Williams W, Joseph P, Ryan S, Sherrard H. Systematic primary PCI for ST-elevation myocardial infarction is feasible for an entire metropolitan area: results of an integrated STEMI program. Can J Card 2006;22(suppl D):131D-2D.
  • Joseph P, Le May MR, Labinaz M, Dionne R, Maloney J, Glover C, Ha A, So D, O’Brien E, Williams W, Froeschl M , Ryan S, Sherrard H, Marquis JF. Systematic ambulance transfer of patients with ST-elevation myocardial infarction from metropolitan hospitals to a specialized heart attack centre for primary angioplasty. Can J Card 2006;22(suppl D):130D.
  • Froeschl M , Provonost A, Ling MC, Le May MR, So D, Glover C. Clinical outcomes associated with the implantation of at least 40 mm of coronary stents: drug-eluting vs bare-metal stents. Presented at the University of Ottawa Heart Institute and Department of Medicine Research Days, 2005.
  • Ling MC, Froeschl M , So D, Marquis JF, O’Brien E, Williams W, Le May MR, Labinaz M, Glover C. Clinical outcomes associated with the use of drug-eluting stents in de novo lesions: “real world” experience from a large volume Canadian center. Can J Card 2005;21(suppl C):237C.
  • Ling MC, Froeschl M , So D, Marquis JF, O’Brien E, Williams W, Le May MR, Labinaz M, Glover C. Clinical outcomes associated with the use of drug-eluting stents for in-stent restenosis lesions. Can J Cardiol 2005;21(suppl C):121C.
  • Froeschl M , So D, Labinaz M, Le May MR. Comparison of epicardial blood flow in primary and tenecteplase-facilitated percutaneous coronary intervention. Can J Cardiol 2004;20(suppl D):152D.
  • So D, Ha A, Froeschl M , Davies R, Wells G, Le May MR. ST-resolution in facilitated percutaneous coronary intervention with tenecteplase versus tenecteplase alone: a CAPITAL-AMI substudy. Can J Cardiol 2004;20 (suppl D):152D and Am J Cardiol 2004;suppl 94(6):17E.

BOOK CHAPTERS

  • Froeschl M , Roberts R. Cardiovascular Diseases Due to Genetic Abnormalities. In O’Rourke RA, Walsh R, Fuster V (eds), Hurst’s the Heart Manual of Cardiology, 12th edition. New York: McGraw-Hill; 2009: 531-45.
Froeschl, Michael

Froeschl, Michael

Froeschl, Michael

MDCM, MSc, FRCPC, FACC
Phone
613-696-7318
Fax
613-696-7244

Appointments and affiliations

Interventional Cardiologist
University of Ottawa Heart Institute

Associate Professor, Department of Medicine
University of Ottawa